Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.514, 2006-01, pp. : 1-1
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Natalizumab benefits QOL in multiple sclerosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 577, 2009-01 ,pp. :
Access to resources
Recommend
. . . and also shows QOL benefits
Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. :
New trimetazidine formulation benefits clinical, QOL status
Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. :